The intracellular form of human MAGP1 elicits a complex and specific transcriptional response

Microfibril-associated glycoprotein-1 (MAGP1) is found associated with microfibrils in the extracellular matrix (ECM). In humans, MAGP1 is expressed as two alternatively spliced isoforms: MAGP1A, the extracellular microfibril-associated form; and MAGP1B, an exclusively intracellular isoform derived from the skipping of exon 3. The biological function of MAGP1B is unknown. We performed gene expression profiling to study the cellular response to MAGP1B using whole-genome genechips. We found that MAGP1B specifically induces the expression of genes linked to cell adhesion, motility, metabolism, gene expression, development and signal transduction. Versican, a gene product involved in the structure and functional regulation of the ECM, showed the highest up-regulation in response to MAGP1B. These studies suggest a dual role for MAGP1, with extracellular MAGP1A involved in ECM function, and intracellular MAGP1B modulating the expression of genes that function in cell adhesion, migration and control of ECM deposition.     

Complementary DNA cloning establishes microfibril-associated glycoprotein (MAGP) to be a discrete component of the elastin-associated microfibrils

Affinity-purified antibodies to microfibril-associated glycoprotein (MAGP) were used to screen a random-primed, bovine nuchal ligament cDNA library in lambda gt11. A 303-base pair clone, cM5, was isolated which encoded an amino acid sequence homologous with that determined directly from a Lys-C peptide of MAGP. A 936-base pair cDNA clone, cM32, was identified in an oligo(dT)-primed cDNA library using plaque hybridization with clone cM5. Clone cM32 encoded amino acid sequences corresponding to sequences obtained from three Lys-C peptides of MAGP, indicating that the clone was an authentic cDNA for the glycoprotein. The cDNA coded for the entire MAGP polypeptide (21 kDa) of 183 amino acids including a putative signal peptide of 17-19 amino acids. This was confirmed by in vitro translation of synthetic mRNAs transcribed from cM32. The amino acid composition of the encoded protein was virtually identical to that previously published for MAGP. DNA sequence analysis of cM32 indicated that MAGP contains two structurally dissimilar regions, an amino-terminal domain containing high levels of glutamine, proline, and acidic amino acids and a carboxyl-terminal domain containing all 13 of the cysteine residues and most of the basic amino acids. Northern blot hybridization of poly(A+) RNA from fetal nuchal ligament with clone cM32 identified a single mRNA species for MAGP of approximately 1.1 kilobases. The evidence indicates that MAGP is a distinct component of 12-nm microfibrils and that it is not derived from a larger microfibrillar glycopolypeptide.     

Identification of a functional proprotein convertase cleavage site in microfibril-associated glycoprotein 2

Microfibril-associated glycoprotein 2 (MAGP2) is a secreted protein associated with multiple cellular activities including the organization of elastic fibers in the extracellular matrix (ECM), angiogenesis, as well as regulating Notch and integrin signaling. Importantly, increases in MAGP2 positively correlate with poor prognosis for some ovarian cancers. It has been assumed that full-length MAGP2 is responsible for all reported effects; however, here we show MAGP2 is a substrate for the proprotein convertase (PC) family of endoproteases. Proteolytic processing of MAGP2 by PC cleavage could serve to regulate secretion and thus, activity and function as reported for other extracellular and cell-surface proteins. In support of this idea, MAGP2 contains an evolutionarily conserved PC consensus cleavage site, and amino acid sequencing of a newly identified MAGP2 C-terminal cleavage product confirmed functional PC cleavage. Additionally, mutagenesis of the MAGP2 PC consensus cleavage site or treatment with PC inhibitors prevented MAGP2 proteolytic processing. Finally, both cleaved and uncleaved MAGP2 were detected extracellularly and MAGP2 secretion appeared independent of PC cleavage, suggesting that PC processing occurs mainly outside the cell. Our characterization of alternative forms of MAGP2 present in the extracellular space not only enhances diversity of this ECM protein but also provides a previously unrecognized molecular mechanism for regulation of MAGP2 biological activity.     

Microfibril-associated Glycoprotein 2 (MAGP2) Loss of Function Has Pleiotropic Effects in Vivo

Microfibril-associated glycoprotein (MAGP) 1 and 2 are evolutionarily related but structurally divergent proteins that are components of microfibrils of the extracellular matrix. Using mice with a targeted inactivation of Mfap5, the gene for MAGP2 protein, we demonstrate that MAGPs have shared as well as unique functions in vivo. Mfap5^−/− mice appear grossly normal, are fertile, and have no reduction in life span. Cardiopulmonary development is typical. The animals are normotensive and have vascular compliance comparable with age-matched wild-type mice, which is indicative of normal, functional elastic fibers. Loss of MAGP2 alone does not significantly alter bone mass or architecture, and loss of MAGP2 in tandem with loss of MAGP1 does not exacerbate MAGP1-dependent osteopenia. MAGP2-deficient mice are neutropenic, which contrasts with monocytopenia described in MAGP1-deficient animals. This suggests that MAGP1 and MAGP2 have discrete functions in hematopoiesis. In the cardiovascular system, MAGP1;MAGP2 double knockout mice (Mfap2^−/−;Mfap5^−/−) show age-dependent aortic dilation. These findings indicate that MAGPs have shared primary functions in maintaining large vessel integrity. In solid phase binding assays, MAGP2 binds active TGFβ1, TGFβ2, and BMP2. Together, these data demonstrate that loss of MAGP2 expression in vivo has pleiotropic effects potentially related to the ability of MAGP2 to regulate growth factors or participate in cell signaling.     

Oophorectomy-induced bone loss is attenuated in MAGP1-deficient mice

Microfibril-associated glycoprotein-1 (MAGP1), together with the fibrillins, are constitutive components of vertebrate microfibrils. Mice deficient in MAGP1 (murine MAGP1 knockout animals (Mfap2(-/-)); MAGP1Δ) is appropriate develop progressive osteopenia and reduced whole bone strength, and have elevated numbers of osteoclasts lining the bone surface. Our previous studies suggested that the increased osteoclast population was associated with elevated levels of receptor activator of NF-κB ligand (RANKL), a positive regulator of osteoclast differentiation. To explore the relationship between RANKL expression and osteoclast differentiation in MAGP1 deficiency, oophorectomy (OVX) was used to stimulate RANKL expression in both WT and MAGP1Δ animals. Bone loss following OVX was monitored using whole body DEXA and in vivo μCT. While WT mice exhibited significant bone loss following OVX, percent bone loss was reduced in MAGP1Δ mice. Further, serum RANKL levels rose significantly in OVX WT mice, whereas, there was only a modest increase in RANKL following OVX in the mutant mice due to already high baseline levels. Elevated RANKL expression was normalized when cultured MAGP1Δ osteoblasts were treated with a neutralizing antibody targeting free TGFβ. These studies provide support for increased RANKL expression associated with MAGP1 deficiency and provide a link to altered TGF-β signaling as a possible causative signaling pathway regulating RANKL expression in MAGP1Δ osteoblasts.     

A prognostic gene signature in advanced ovarian cancer reveals a microfibril-associated protein (MAGP2) as a promoter of tumor cell survival and angiogenesis

Ovarian cancer is the most lethal gynecologic cancer, and this is largely related to its late diagnosis. High grade serous cancers often initially respond to chemotherapy, resulting in a better survival rate, compared to other ovarian carcinoma subtypes. We review recent work identifying a survival-associated gene expression profile for advanced serous ovarian cancer. Within this signature, the authors identified MAGP2, also known as microfibrillar associated protein 5 (MFAP5), as a highly significant indicator of survival and chemosensitivity. MAGP2 is a multifunctional secreted protein—important for elastic microfibril assembly and modulating endothelial cell behavior—with a newly identified role in cell survival. Through α_Vβ₃ integrin-mediated signaling, MAGP2 promotes tumor and endothelial cell survival and endothelial cell motility, providing a potential mechanistic link between MAGP2 and angiogenesis as well as patient survival.Key words: ovarian cancer, cell survival, MAGP2, α_Vβ₃, endothelial cellAmong reproductive cancers, ovarian cancer has the highest associated mortality rate-the majority of patients present with late—stage disease that has already spread beyond the ovaries.¹ Surgery and chemotherapy are used to eliminate localized and metastatic cancer cells, and the size of the residual legion after surgery is the main prognostic factor for survival. Biomarkers or gene expression profiles associated with prognosis or chemosensitivity in different ovarian cancer subtypes could aid treatment decisions—perhaps improving patient mortality rates by identifying patients that will not respond to traditional surgical or chemotherapeutic approaches. While the underlying mechanisms for ovarian cancer are incompletely understood, cellular alterations important for cancer initiation and progression have been described.² Distinguishing features of cancer cells include the ability to survive and proliferate under adverse conditions, induce and maintain angiogenesis, and invade into the surrounding tissues. The contribution of secreted proteins to these processes is of particular interest, as these proteins can modulate cell signaling in both tumor and normal cells. This review summarizes recent work by Mok et al.³ describing the identification of a gene expression signature correlating with serous ovarian cancer survival and chemosensitivity. They validate the secreted protein, Microfibril-Associated Glycoprotein 2 (MAGP2), gene name, MFAP5 (also known as microfibrillar associated protein 5), as an independent prognostic biomarker of survival and chemosensitivity and report a role for MAGP2 in cell survival.To identify a gene expression signature predicting survival in late stage, high-grade papillary serous ovarian tumors, the authors used laser capture microdissection to isolate epithelial cancer cells from paraffin-embedded tissue and analyzed gene expression changes using microarrays. The authors were able to identify and validate a gene expression signature that correlated with survival in this patient cohort. The median hazard ratio was used as a threshold to group high- and low-risk patients and the representative Kaplan Meier curves were compared using the log-rank test, revealing a significant association between the high-risk group and shorter survival times. Of all the genes examined, microfibril-associated glycoprotein 2 (MAGP2) had the highest correlation with poor patient prognosis. MAGP2 expression was further explored as an independent prognostic marker, at both the mRNA and protein levels. Mok and colleagues confirmed increased MAGP2 expresssion by both real time PCR and immunohistochemical staining. Both high MAGP2 mRNA and protein levels stratified the low and high risk patient groups, with positive MAGP2 predicting a poor prognosis.To explore the signaling pathways affecting ovarian cancer patient survival, the authors compared gene expression profiles from the advanced stage ovarian cancer samples to those from normal ovarian surface epithelial cells and compared them with the patient survival gene signature. The α_Vβ₃ integrin receptor was found to be a central signaling pathway in this network. MAGP2 binds and activates α_Vβ₃ integrin, and the downstream effectors, focal adhesion kinase (FAK), paxillin (PXN), growth factor receptor-bound protein 2 (GRB2) and son of sevenless homolog 1 (SOS 1) were overexpressed. These may contribute toward cell cycle progression and increased cell survival. Changes in a subset of these genes, including FAK and MAGP2, were verified using quantitative Real Time-PCR, indicating that the α_Vβ₃ signaling pathway is over-activated in ovarian cancer. Given that α_Vβ₃ integrin signaling correlated with chemotherapy resistance in ovarian cancer cell lines,⁴ the authors also examined the utility of MAGP2 as an indicator of chemosensitivity. By stratifying patients based on response to chemotherapy, the authors determined that high MAGP2 levels correlate with chemoresistance—suggesting that these patients might require alternative treatment strategies to improve patient outcome.To characterize the role of secreted MAGP2 in modulating tumor and endothelial cells via α_Vβ₃ integrin, an important mediator of cell adhesion and survival, the authors initially employed an in vitro approach. Ovarian cancer cell lines were screened for MAGP2 and α_Vβ₃ integrin expression and were evaluated for their ability to adhere to synthetic MAGP2 protein. Cell lines with (A224, OVCA429 and SKOV3) and without (UCI107) α_Vβ₃ integrin were used. A224 cell adhesion to MAGP2 was diminished in the presence of a α_Vβ₃ integrin blocking antibody, whereas no change in UCI107 cell adhesion was observed, demonstrating a role for MAGP2 in α_Vβ₃ integrin-mediated adhesion. Improved OVCA429 cell survival in serum-free media was also observed in the presence of recombinant MAGP2, suggesting that MAGP2 is important for both α_Vβ₃ integrin-mediated tumor cell survival and adhesion (Fig. 1).Open in a separate windowFigure 1Ovarian serous cancer cells secrete MAGP2, which acts to increase tumor cell survival and endothelial cell motility and survival through the α_Vβ₃ integrin.Previous reports have demonstrated a role for MAGP2 in elastic fiber assembly⁵ and endothelial cell behavior.^6,7 The ability of MAGP2 to modulate endothelial cell behavior via α_Vβ₃ integrin was next examined. The authors observed an increase in human umbilical vein endothelial cell (HUVEC) adhesion to recombinant MAGP2, which was inhibited by pre-incubation with a α_Vβ₃ integrin antibody. HUVEC survival in the absence of serum, and cell motility and invasion were also increased by MAGP2 (Fig. 1). The MAGP2 protein sequence includes the classical integrin-binding RGD domain. To determine whether this domain was important for MAGP2-mediated alterations in endothelial cell behavior, the authors generated recombinant proteins with amino acid substitutions in the RGD motif. Enhanced MAGP2-mediated cell motility was diminished in the presence of α_Vβ₃ integrin blocking antibody or mutated recombinant MAGP2, but not with α₅ or β₁ integrin blocking antibodies, demonstrating the MAGP2 RGD motif was important for α_Vβ₃ integrin signaling in endothelial cells. To further explore MAGP2-mediated changes in endothelial cells, microarray analysis was used to compare gene expression profiles in MAGP2-treated and untreated HUVEC cells. Increased expression of genes involved in cell adhesion such as FAK (focal adhesion kinase) and ITGAV (integrin alpha v) were observed, together with increased cell motility genes, such as CDC42 and APC, while an increase in phosphorylated FAK was observed via western blotting. These data provide mechanistic insight into MAGP2-modulation of cellular activity.To understand MAGP2 function during tumorigenesis, the authors generated SKOV3 ovarian cancer clonal cell lines stably expressing either an empty vector or shRNA against MAGP2. The authors evaluated the ability of subcutaneously injected cells to form tumors in nude mice, showing that cells with reduced MAGP2 expression formed smaller tumors than controls. This effect was confirmed using additional MAGP2-targeting shRNAs in both SKOV3 and OVCAR3 cells. Finally, as MAGP2 affects endothelial cell behavior, the effects on the angiogenic microenvironment was evaluated. Immunohistochemical analysis of MAGP2-knockdown tumor tissue in mice revealed decreased microvessel density (MVD) as visualized by CD34⁺ staining, while MVD and MAGP2 expression significantly correlated in 30 human serous ovarian cancer tissue specimens. Together these data suggest an in vivo role for MAGP2 in promoting angiogenesis.     

A prognostic gene signature in advanced ovarian cancer reveals a microfibril-associated protein (MAGP2) as a promoter of tumor cell survival and angiogenesis

Ovarian cancer is the most lethal gynecologic cancer, and this is largely related to its late diagnosis. High grade serous cancers often initially respond to chemotherapy, resulting in a better survival rate, compared to other ovarian carcinoma subtypes. We review recent work identifying a survival-associated gene expression profile for advanced serous ovarian cancer. Within this signature, the authors identified MAGP2, also known as microfibrillar associated protein 5 (MFAP5), as a highly significant indicator of survival and chemosensitivity. MAGP2 is a multifunctional secreted protein—important for elastic microfibril assembly and modulating endothelial cell behavior—with a newly identified role in cell survival. Through αvβ3 integrin-mediated signaling, MAGP2 promotes tumor and endothelial cell survival and endothelial cell motility, providing a potential mechanistic link between MAGP2 and angiogenesis as well as patient survival.     

Identification of a Novel Gene (ECM2) Encoding a Putative Extracellular Matrix Protein Expressed Predominantly in Adipose and Female-Specific Tissues and Its Chromosomal Localization to 9q22.3

We isolated by the differential display technique a novel gene that was expressed abundantly in adipose and female-specific tissues. The cDNA contained an open reading frame of 2097 nucleotides encoding a 699-amino-acid peptide. The predicted protein showed homology to several known extracellular matrix (ECM) proteins such as proteoglycan, keratocan, and decorin. Moreover, the amino acid sequence contained several possible functional domains that would participate in protein–protein interactions, including an RGD sequence, a von Willebrand factor domain (VWFC), and a leucine-rich repeat. These findings suggest that this novel protein functions in cell–cell and/or cell–ECM recognition processes. Northern blot analysis revealed expression predominantly in adipose tissue as well as female-specific organs such as mammary gland, ovary, and uterus among 20 human adult tissues examined. We assigned the gene to chromosome 9q22.3 by means of fluorescencein situhybridization.     

Regulation of cell migration and survival by focal adhesion targeting of Lasp-1

Large-scale proteomic and functional analysis of isolated pseudopodia revealed the Lim, actin, and SH3 domain protein (Lasp-1) as a novel protein necessary for cell migration, but not adhesion to, the extracellular matrix (ECM). Lasp-1 is a ubiquitously expressed actin-binding protein with a unique domain configuration containing SH3 and LIM domains, and is overexpressed in 8-12% of human breast cancers. We find that stimulation of nonmotile and quiescent cells with growth factors or ECM proteins facilitates Lasp-1 relocalization from the cell periphery to the leading edge of the pseudopodium, where it associates with nascent focal complexes and areas of actin polymerization. Interestingly, although Lasp-1 dynamics in migratory cells occur independently of c-Abl kinase activity and tyrosine phosphorylation, c-Abl activation by apoptotic agents specifically promotes phosphorylation of Lasp-1 at tyrosine 171, which is associated with the loss of Lasp-1 localization to focal adhesions and induction of cell death. Thus, Lasp-1 is a dynamic focal adhesion protein necessary for cell migration and survival in response to growth factors and ECM proteins.     

A novel intracellular fibulin-1D variant binds to the cytoplasmic domain of integrin beta 1 subunit

Fibulin-1 is a member of a growing family of proteins that includes eight members and is involved in cellular functions such as adhesion, migration and differentiation. Fibulin-1 has also been implicated in embryonic development of the heart and neural crest-derived structures. It is an integral part of the extracellular matrix (ECM) and has been shown to bind to a multitude of ECM proteins. However, fibulin-1 was first identified as a protein purified from placental extracts that binds to the cytoplasmic domain of integrin β1. Human fibulin-1 is alternatively spliced into four different isoforms namely A–D. These isoforms share a common N-terminus sequence that contains a secretion sequence but differ in their carboxy-terminal fibulin-1 module. In this report we identify a new splice variant of fibulin-1 that differs from all other fibulin-1 variants in the N-terminus sequence and has a similar carboxy-terminus sequence as fibulin-1D. This variant that we named fibulin-1D prime (fibulin-1D′) lacks a secretion sequence and the anaphlatoxin region of fibulin-1 variants. The protein has an apparent molecular weight of 70.5 kDa. Herein we show that fibulin-1D′ binds to the intracellular domain of integrin β1 as well as to integrin α5β1. The protein was localized intracellularly in CHO cells transfected with a pEF4 plasmid containing full-length coding sequence of fibulin-1D′. We also localized the protein in human placenta. We propose that the fibulin-1D′ variant might play a role in early embryo development as well as in modulating integrin β1 functions including adhesion and motility.     

CHIP: a link between the chaperone and proteasome systems

CHIP, carboxy terminus of Hsc70 interacting protein, is a cytoplasmic protein whose amino acid sequence is highly conserved across species. It is most highly expressed in cardiac and skeletal muscle and brain. The primary amino acid sequence is characterized by 3 domains, a tetratricopeptide repeat (TPR) domain at its amino terminus, a U-box domain at its carboxy terminus, and an intervening charged domain. CHIP interacts with the molecular chaperones Hsc70-Hsp70 and Hsp90 through its TPR domain, whereas its U-box domain contains its E3 ubiquitin ligase activity. Its interaction with these molecular chaperones results in client substrate ubiquitylation and degradation by the proteasome. Thus, CHIP acts to tilt the folding-refolding machinery toward the degradative pathway, and it serves as a link between the two. Because protein degradation is required for healthy cellular function, CHIP's ability to degrade proteins that are the signature of disease, eg, ErbB2 in breast and ovarian cancers, could prove to be a point of therapeutic intervention.     

Sequence-specific DNA recognition by the Myb-like domain of plant telomeric protein RTBP1

We have identified a rice gene encoding a DNA-binding protein that specifically recognizes the telomeric repeat sequence TTTAGGG found in plants. This gene, which we refer to as RTBP1 (rice telomere-binding protein 1), encodes a polypeptide with a predicted molecular mass of 70 kDa. RTBP1 is ubiquitously expressed in various organs and binds DNA with two or more duplex TTTAGGG repeats. The predicted protein sequence includes a single domain at the C terminus with extensive homology to Myb-like DNA binding motif. The Myb-like domain of RTBP1 is very closely related to that of other telomere-binding proteins, including TRF1, TRF2, Taz1p, and Tbf1p, indicating that DNA-binding domains of telomere-binding proteins are well conserved among evolutionarily distant species. To obtain precise information on the sequence of the DNA binding site recognized by RTBP1, we analyzed the sequence-specific binding properties of the isolated Myb-like domain of RTBP1. The isolated Myb-like domain was capable of sequence-specific DNA binding as a homodimer. Gel retardation analysis with a series of mutated telomere probes revealed that the internal GGGTTT sequence in the two-telomere repeats is critical for binding of Myb-like domain of RTBP1, which is consistent with the model of the TRF1.DNA complex showing that base-specific contacts are made within the sequence GGGTTA. To the best of our knowledge, RTBP1 is the first cloned gene in which the product is able to bind double-stranded telomeric DNA in plants. Because the Myb-like domain appears to be a significant motif for a large class of proteins that bind the duplex telomeric DNA, RTBP1 may play important roles in plant telomere function in vivo.     

Cloning and recombinant expression of the La RNA-binding protein from Trypanosoma brucei

We report the isolation, cloning and recombinant expression of a Trypanosoma brucei homolog of the La RNA-binding protein. Based on peptide sequence information we have isolated a cDNA clone which encodes a protein of 335 amino acids with a predicted molecular weight of 37.7 kDa. The amino acid sequence fits the domain structure of known La proteins and contains a putative ATP-binding site located in the COOH-terminal domain. The cDNA was expressed as a glutathione S-transferase fusion protein in Escherichia coli, and the recombinant protein displayed RNA-binding activity in an electrophoretic mobility shift assay.     

Characterization of a novel serine/threonine kinase associated with nuclear bodies

A novel protein kinase, Mx-interacting protein kinase (PKM), has been identified in a yeast two-hybrid screen for interaction partners of human MxA, an interferon-induced GTPase with antiviral activity against several RNA viruses. A highly conserved protein kinase domain is present in the N-terminal moiety of PKM, whereas an Mx interaction domain overlaps with C-terminal PEST sequences. PKM has a molecular weight of about 127,000 and exhibits high sequence homology to members of a recently described family of homeodomain-interacting protein kinases. Recombinant PKM has serine/threonine kinase activity that is abolished by a single amino acid substitution in the ATP binding domain (K221W). PKM catalyzes autophosphorylation and phosphorylation of various cellular and viral proteins. PKM is expressed constitutively and colocalizes with the interferon-inducible Sp100 protein and murine Mx1 in discrete nuclear structures known as nuclear bodies.     

Cloning and characterization of AWP1, a novel protein that associates with serine/threonine kinase PRK1 in vivo

We describe the cloning and expression of cDNAs encoding a novel human protein of 208 amino acid residues with a predicted molecular mass of 22.6kDa and its mouse homologue. We name this protein as AWP1 (associated with PRK1). AWP1 is a ubiquitously expressed protein, and the Awp1 gene is switched on during early human and mouse development. When expressed in COS-1 cells, the Myc-tagged AWP1 has an apparent molecular mass higher than that deduced from its amino acid sequence. AWP1 possesses a conserved zf-A20 zinc finger domain at its N-terminal and a zf-AN1 zinc finger domain at its C-terminal. Co-immunoprecipitation experiments revealed that mouse AWP1 specifically interacts with a rat serine/threonine protein kinase PRK1 in vivo. Hence, AWP1 may play a regulatory role in mammalian signal transduction pathways.     

Identification of tranilast-binding protein as 36-kDa microfibril-associated glycoprotein by drug affinity chromatography, and its localization in human skin

To elucidate the molecular mechanism involved in the suppression of keloids and hypertrophic scars by tranilast, we investigated the target protein of tranilast in bovine skin and aorta. A specific tranilast-binding protein was isolated from both tissues by drug affinity chromatography and was identified as 36-kDa microfibril-associated glycoprotein (36-kDa MAGP). Binding of 36-kDa MAGP to tranilast seemed to be specific since 36-kDa MAGP could be eluted from the drug affinity column by tranilast itself and also binding of 36-kDa MAGP to other anti-allergy drugs (amlexanox and cromolyn) is significantly weaker than that to tranilast. Light and electron microscopic immunohistochemistry detected the protein at the periphery of elastic fibers in normal human skin. In hypertrophic scar tissue, however, 36-kDa MAGP was located on small bundles of microfibrils. These findings provide support for the concept that elastogenesis occurs in scar tissue and 36-kDa MAGP might be one of the targets for tranilast.